TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25821098

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of proton pump inhibitor (PPI)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Bolus injection of proton pump inhibitor (PPI)
Number of subjects: 273
Study: 23307404

Group type: EXPERIMENTAL
Intervention: CHO-PRO (0.8 g sucrose · kg‐1 · hr‐1 with 0.3 g · kg‐1 · hr‐1 whey-protein isolate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHO (0.8 g sucrose · kg‐1 · hr‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHO-CHO (1.1 g sucrose · kg‐1 · hr‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHO-PRO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 20805294

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (n=90)
Number of subjects: 188
Study: 18077611

Group type: EXPERIMENTAL
Intervention: Refrigerated formulation of Zostavax (n = 182)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Frozen formulation of Zostavax (n = 185)
Number of subjects: 367
Study: 16162683

Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition (PEN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 50
Study: 11895877

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10197490

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Ethanolamine oleate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 7549381

Group type: EXPERIMENTAL
Intervention: 10% Cantharides extract
Number of subjects: 50
Study: 2249379

Group type: EXPERIMENTAL
Intervention: 75 mg codeine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6108299

Group type: EXPERIMENTAL
Intervention: 2 mg of lorazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg of oxazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg of temazepam
Number of subjects: 20
Study: 29033116

Group type: EXPERIMENTAL
Intervention: Accurate norms information (experimental group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fun facts (control group)
Number of subjects: 68
Study: 26996542

Group type: EXPERIMENTAL
Intervention: Integrated bihormonal artificial pancreas
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (insulin pump therapy)
Number of subjects: 10
Study: 24614112

Group type: EXPERIMENTAL
Intervention: Green tea extract (500 mg, three times a day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cellulose (placebo, 500 mg, three times a day)
Number of subjects: 92
Study: 22587593

Group type: EXPERIMENTAL
Intervention: GAD-alum
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20626364

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 17903568

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocodone with acetaminophen
Number of subjects: 60
Study: 16243052

Group type: EXPERIMENTAL
Intervention: Repetition of printed words with varying word frequency and case alternation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lexical decision task (LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naming task (NAM)
Number of subjects: 0
Study: 12234038

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 10422530

Group type: EXPERIMENTAL
Intervention: Increased luminance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback about low light levels
Number of subjects: 0
Study: 8525411

Group type: EXPERIMENTAL
Intervention: Vaginal scrubbing with 10% povidone‐iodine immediately prior to the operation (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine vaginal scrubbing followed by abdominal scrubbing (Group I)
Number of subjects: 30
Study: 2147833

Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg by rapid intravenous injection every 8 hours for 48 hours)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment (furosemide, nitrates, dopamine‐dobutamine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study: 6994771

Group type: EXPERIMENTAL
Intervention: Guanfacine 2.0 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Guanfacine 1.0 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clonidine 0.30 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg and 0.30 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31764741

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 1 g
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous acetaminophen 1 g
Number of subjects: 75
Study: 27932535

Group type: EXPERIMENTAL
Intervention: Traditional multiple-set resistance exercise (TR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Circuit resistance exercise (CI)
Number of subjects: 14
Study: 27052065

Group type: EXPERIMENTAL
Intervention: Preintubation airway assessment using adult fiberoptic bronchoscope (FOB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Blind placement of DLETTs and BBs followed by clinical confirmation by auscultation
Number of subjects: 84
Study: 23335452

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intensive group cognitive treatment (IGCT)
Number of subjects: 54
Study: 22801833

Group type: EXPERIMENTAL
Intervention: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed) for 6 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed)
Number of subjects: 107
Study: 19178748

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopy-assisted vaginal hysterectomy
Number of subjects: 0
Study: 17550443

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment with a 530- to 750-nm filter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 30
Study: 15878166

Group type: EXPERIMENTAL
Intervention: Infants (4-month-olds) responding to color categorization in a target detection task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adults responding to color categorization in a target detection task.
Number of subjects: 0
Study: 12162603

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 19
Study: 10217341

Group type: EXPERIMENTAL
Intervention: Oral sustained release morphine (MST)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rectal morphine sulfate suppositories (MSR)
Number of subjects: 6
Study: 1346956

Group type: EXPERIMENTAL
Intervention: Once daily gentamicin (4 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice daily gentamicin (4 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both dosage schedules of gentamicin
Number of subjects: 20
Study: 6465510

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion + 400 mg cimetidine i.m. 120 min before histamine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Histamine-induced effects without premedication
Number of subjects: 8
Study: 29200001

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage 3 times a week for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 46
Study: 29698253

Group type: EXPERIMENTAL
Intervention: Icon alarms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard alarms
Number of subjects: 20
Study: 27672108

Group type: EXPERIMENTAL
Intervention: Copanlisib at a maximum tolerated dose (MTD) of 0.8 mg/kg, administered as three weekly intravenous infusions per 28-day cycle.
Number of subjects: 57
Study: 25427070

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/ml) after paring the hyperkeratotic tissue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simple paring
Number of subjects: 50
Study: 23829408

Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours, using the 30° tilt
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard care, repositioned every 6 hours, using the 90° lateral rotation
Number of subjects: 213
Study: 19880803

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Bucindolol (α2C wild type)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Bucindolol (α2C Del carriers)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1040
Study: 18945992

Group type: EXPERIMENTAL
Intervention: Growth hormone (20 microg/kg per day)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 16640637

Group type: EXPERIMENTAL
Intervention: Positive information about pain during ET (experimental group)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Informative paragraphs (control groups)
Number of subjects: 437
Study: 12634581

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 300/75 mg/m2 twice daily (after initial dosing of 230/57.5 mg/m2 or 300/75 mg/m2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 300/75 mg/m2 twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 100
Study: 11314239

Group type: EXPERIMENTAL
Intervention: Clodronate (100 mg i.m./14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhaled corticosteroid treatment (fluticasone or beclomethasone) without clodronate
Number of subjects: 60
Study: 9033521

Group type: EXPERIMENTAL
Intervention: Educational program in nursing homes
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 1152
Study: 8070823

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day plus aspirin and calcium blockers
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional treatment (aspirin and calcium blockers)
Number of subjects: 95
Study: 3554456

Group type: EXPERIMENTAL
Intervention: TMP-SMZ-carbenicillin regimen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TMP-SMZ (oral)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TMP-SMZ (intravenous)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TMP-SMZ in combination with aminoglycoside or antipseudomonal penicillin
Number of subjects: 126
Study: 29280076

Group type: EXPERIMENTAL
Intervention: Titanium curettes (TC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stainless steel ultrasonic tip (PS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythritol air‐polishing powder (EP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rubber cup polishing (CON)
Number of subjects: 18
Study: 26492541

Group type: COMPARATOR
Intervention: CIO (Complete Insulin Orders)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: NPH-CIO (NPH plus CIO)
Number of subjects: 61
Study: 24356795

Group type: EXPERIMENTAL
Intervention: 2g purified EPA/DHA for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Olive oil (placebo) for 6 weeks
Number of subjects: 34
Study: 22865311

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in smokers with short time to treatment (<3 hours)
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis in smokers with short time to treatment (<3 hours)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in non-smokers with short time to treatment (<3 hours)
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis in non-smokers with short time to treatment (<3 hours)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in patients with >3 hours to treatment
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis in patients with >3 hours to treatment
Number of subjects: 1572
Study: 20651010

Group type: EXPERIMENTAL
Intervention: Higher-intensity, individualized (HI) treadmill training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower-intensity, generalized (LG) treadmill training
Number of subjects: 30
Study: 18759320

Group type: EXPERIMENTAL
Intervention: Moderate Physical Activity (MPA)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity (VPA)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Overall Physical Activity adherence
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Comparison of adherence between genders
Number of subjects: 255
Study: 16444910

Group type: EXPERIMENTAL
Intervention: D-003 5 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D-003 10 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Policosanol 5 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Policosanol 10 mg/day
Number of subjects: 100
Study: 12750868

Group type: EXPERIMENTAL
Intervention: 0.06 IU hGH/kg BW per day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10496201

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study: 8929439

Group type: EXPERIMENTAL
Intervention: Phentolamine (1 mg/kg IV over 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (IV)
Number of subjects: 0
Study: 1676246

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6835985

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30365464

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Everolimus (early initiation trials)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control
Number of subjects: 349
Study: 30015250

Group type: EXPERIMENTAL
Intervention: Rocket stove (intervention)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Mixed use of intervention and traditional stoves
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Exclusive and mixed stove users
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (traditional stoves)
Number of subjects: 222
Study: 27271662

Group type: EXPERIMENTAL
Intervention: MWP_CANBol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CANPBol
Number of subjects: 0

Group type: COMPARATOR
Intervention: WWB
Number of subjects: 0
Study: 25160013

Group type: EXPERIMENTAL
Intervention: GTE2 (2 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GTE4 (4 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GTE6 (6 g/d)
Number of subjects: 30
Study: 23067900

Group type: EXPERIMENTAL
Intervention: Radial approach (n = 83)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Femoral approach (n = 77)
Number of subjects: 160
Study: 19220616

Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 288
Study: 17261427

Group type: EXPERIMENTAL
Intervention: Over-the-counter medications
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Drug-related problems
Number of subjects: 87
Study: 15123533

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 42
Study: 11777497

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BARS
Number of subjects: 0
Study: 11477858

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection combined with chemotherapy (Group A)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Chemotherapy (Group C)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (Group B)
Number of subjects: 182
Study: 8588267

Group type: EXPERIMENTAL
Intervention: Flavoxate treatment (1,200 mg/day, 400 mg t.i.d. for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 70
Study: 2523634

Group type: EXPERIMENTAL
Intervention: Chronic enoximone therapy (1 and 2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study: 1094871

Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride nebulization
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride and placebo nebulizations
Number of subjects: 19
Study: 31415883

Group type: EXPERIMENTAL
Intervention: Salmonella typhoid vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 20
Study: 28691557

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (group A, 35 participants)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No prophylaxis (group B, 18 participants)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (group C, 24 participants)
Number of subjects: 109
Study: 26183021

Group type: EXPERIMENTAL
Intervention: TBCT (Traditional Behavioral Couple Therapy)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IBCT (Integrative Behavioral Couple Therapy)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TBCT couples
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IBCT couples
Number of subjects: 104
Study: 24353022

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 or 100 mg
Number of subjects: 378

Group type: COMPARATOR
Intervention: Oxycodone IR 5 or 10 mg
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 378

Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 378
Study: 21462153

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pharmacological therapy alone (Control)
Number of subjects: 41
Study: 18272933

Group type: EXPERIMENTAL
Intervention: Exercise (EX=60 min cycling at 60% VO(2peak))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CT=no exercise)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal-weight (NW)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overweight (OW)
Number of subjects: 20
Study: 16801653

Group type: EXPERIMENTAL
Intervention: Cranial three-dimensional TOF MRA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upper extremity digital subtraction venography (DSV) and thoracic inlet MRI
Number of subjects: 10
Study: 14578078

Group type: EXPERIMENTAL
Intervention: 1 presentation of the standard duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 presentations of the standard duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 presentations of the standard duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of feedback on performance accuracy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of feedback on performance accuracy
Number of subjects: 0
Study: 11094583

Group type: EXPERIMENTAL
Intervention: oral clonidine 2 micrograms kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: oral clonidine 4 micrograms kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 90
Study: 8982892

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 1473445

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug, simvastatin
Number of subjects: 321
Study: 6628810

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) at three dose levels
Number of subjects: 6
Study: 31680600

Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine infusion
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30832708

Group type: EXPERIMENTAL
Intervention: ICPS programme delivered by an internal early teacher
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ICPS programme delivered by an external early teacher
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29642312

Group type: COMPARATOR
Intervention: Maltitol oral spray
Number of subjects: 81

Group type: COMPARATOR
Intervention: Xylitol chewing gum
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 25876529

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (DSM 17938) at a dose of 10^8 colony forming units
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (identical formulation without live micro-organisms)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (DSM 17938)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23810881

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 20162373

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), average of ten sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40
Study: 19597054

Group type: EXPERIMENTAL
Intervention: Alcohol intake of 5 to 14.9 g/d
Number of subjects: 26399

Group type: EXPERIMENTAL
Intervention: Mediating factors (lipids, hemoglobin A1c/diabetes, inflammatory/hemostatic factors, blood pressure factors)
Number of subjects: 26399

Group type: EXPERIMENTAL
Intervention: All mediating factors
Number of subjects: 26399